Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis. Evaluation and prognosis based on the study of 104 cases.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D001623:Betamethasone / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010248:Paramethasone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D011565:Psoriasis / Q000188:drug therapy* / Q000401:mortality; D014221:Triamcinolone / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D005493:Folic Acid Antagonists; D014221:Triamcinolone; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D001623:Betamethasone; D011239:Prednisolone; D010248:Paramethasone; D006854:Hydrocortisone; D008727:Methotrexate